NAD+ (500mg)

Nicotinamide adenine dinucleotide, oxidised form. NAD+ is the coenzyme that ferries electrons through cellular respiration and also acts as the substrate for sirtuins, PARPs and CD38. Because its levels in tissue fall as we age, it and its precursors have become a focus of longevity research. In research grade, NAD+ features in enzyme assays and redox studies.

Sirtuin activity: deacetylation that depends on NAD+. DNA repair: availability of substrate for PARP. Mitochondrial respiration: the ratio of NAD+ to NADH. Ageing biology: the decline in NAD+ that comes with age. Rodent experiments that restore NAD+ by way of precursors such as NMN and NR report improvements in mitochondrial function and metabolic markers with age. In humans, precursor trials consistently raise blood NAD+ while producing only modest functional endpoints. Clinics study NAD+ given directly for an assortment of unproven indications.

In humans, trials of NAD+ precursors dependably lifted blood NAD+ while changing functional endpoints only modestly; in rodents, NAD+ restoration reported better mitochondrial function with age. Direct NAD+ administration is under clinical study for unproven indications.

Given intravenously in clinics, NAD+ is linked to flushing, nausea and chest tightness during the infusion. The research powder is meant for laboratory use.

In the published NAD+ research, the amounts used were Two 500 mg NMN tablets, Twice daily in human rct, n=30; oral nmn tablets (Pencina KM et al. (2023)); 1,000 mg NR in human phase i rct, n=30; oral nr (Brakedal B et al. (2022)); 1 g NR, Per day in human crossover rct, n=12; oral nr (Elhassan YS et al. (2019)). These are the figures each study reports for its own model, listed in full in the dosage table on this page with links to PubMed. Peptide Aus supplies NAD+ for in-vitro research and does not give dosing guidance for people.

Outside research supply, clinics provide NAD+ infusions and injections, and the so-called 'NAD+ pens' are unregulated devices. What Peptide Aus offers is research-grade NAD+ powder in a 500mg vial for laboratory use.

Cells convert the precursors NMN and NR into NAD+, whereas NAD+ is already the finished coenzyme.

Their roles differ: NAD+ carries electrons and supplies sirtuins, while glutathione buffers oxidation.

Unlike the microgram quantities of signalling peptides, NAD+ is handled at the milligram-to-gram scale, so it calls for a bigger reconstitution volume of roughly 5 mL.

Add about 5 mL of bacteriostatic water slowly down the inside of the vial and swirl gently; do not shake. 500mg in 5 mL gives 100 mg/mL. Refrigerate at 2–8 °C after reconstitution and use within 8–12 weeks. The calculator has this vial preset.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

In Australia, NAD+ holds no Therapeutic Goods Administration (TGA) registration as a medicine and carries no approval for use in humans or animals. The material is offered by Peptide Aus strictly as a research reagent intended for in-vitro laboratory work. The Poisons Standard and the Therapeutic Goods Act set the rules for supplying any substance for human use in this country, and lawful use of the material rests with the buyer. Anyone seeking treatment should consult a doctor.

Directly from Peptide Aus, from Australian stock: NAD+ (500mg) is $129.99 AUD including GST. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.